tiprankstipranks
Precigen, Inc. (CH:I5X)
NASDAQ:I5X
Switzerland Market
I5X
Precigen
RESEARCH TOOLSreports

Precigen (I5X) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

I5X Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Precigen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

I5X Stock 12 Month Forecast

Average Price Target

CHF10.05
Based on 2 Wall Street analysts offering 12 month price targets for Precigen in the last 3 months. The average price target is CHF10.05 with a high forecast of CHF11.26 and a low forecast of CHF8.85. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"CHF2","7":"CHF7","12":"CHF12","4.5":"CHF4.5","9.5":"CHF9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.25858972,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF11.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.05231225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF10.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.84603478,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF8.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.5,7,9.5,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.948,4.510353055384615,5.07270611076923,5.635059166153846,6.197412221538461,6.759765276923076,7.322118332307692,7.884471387692307,8.446824443076922,9.009177498461538,9.571530553846154,10.133883609230768,10.696236664615384,{"y":11.25858972,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.948,4.417562480769231,4.887124961538461,5.356687442307692,5.826249923076923,6.295812403846154,6.765374884615385,7.234937365384615,7.704499846153846,8.174062326923076,8.643624807692307,9.113187288461537,9.58274976923077,{"y":10.05231225,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.948,4.324771906153846,4.701543812307692,5.078315718461538,5.455087624615384,5.831859530769231,6.208631436923077,6.585403343076923,6.96217524923077,7.338947155384615,7.715719061538461,8.092490967692308,8.469262873846153,{"y":8.84603478,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.948,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.948,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF11.26Average Price TargetCHF10.05Lowest Price TargetCHF8.85
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:I5X
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
CHF11.26
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: ImmunityBio (NASDAQ: IBRX), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Precigen (NASDAQ: PGEN)
Citizens JMP Analyst forecast on CH:I5X
Jason Butler
Citizens JMP
Citizens JMP
CHF7.24→CHF8.85
Buy
―
Reiterated
05/14/26
Precigen price target raised to $11 from $9 at CitizensPrecigen price target raised to $11 from $9 at Citizens
Cantor Fitzgerald Analyst forecast on CH:I5X
Jennifer Kim
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
09/26/25
Cantor Fitzgerald Sticks to Their Buy Rating for Precigen (PGEN)
J.P. Morgan Analyst forecast on CH:I5X
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Hold
―
Upgraded
08/15/25
Precigen upgraded to Neutral from Underweight at JPMorganPrecigen upgraded to Neutral from Underweight at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:I5X
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
CHF11.26
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: ImmunityBio (NASDAQ: IBRX), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Precigen (NASDAQ: PGEN)
Citizens JMP Analyst forecast on CH:I5X
Jason Butler
Citizens JMP
Citizens JMP
CHF7.24→CHF8.85
Buy
―
Reiterated
05/14/26
Precigen price target raised to $11 from $9 at CitizensPrecigen price target raised to $11 from $9 at Citizens
Cantor Fitzgerald Analyst forecast on CH:I5X
Jennifer Kim
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
09/26/25
Cantor Fitzgerald Sticks to Their Buy Rating for Precigen (PGEN)
J.P. Morgan Analyst forecast on CH:I5X
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Hold
―
Upgraded
08/15/25
Precigen upgraded to Neutral from Underweight at JPMorganPrecigen upgraded to Neutral from Underweight at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Precigen

3 Months
Jason ButlerCitizens JMP
Success Rate
17/29 ratings generated profit
59%
Average Return
+19.79%
Copying Jason Butler's trades and holding each position for 3 Months would result in 58.62% of your transactions generating a profit, with an average return of +19.79% per trade.
1 Year
Jason ButlerCitizens JMP
Success Rate
17/29 ratings generated profit
59%
Average Return
+62.60%
Copying Jason Butler's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +62.60% per trade.
2 Years
Jason ButlerCitizens JMP
Success Rate
20/29 ratings generated profit
69%
Average Return
+132.00%
Copying Jason Butler's trades and holding each position for 2 Years would result in 68.97% of your transactions generating a profit, with an average return of +132.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

I5X Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
2
3
10
9
8
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
3
10
9
8
In the current month, I5X has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. I5X average Analyst price target in the past 3 months is 10.05.
Each month's total comprises the sum of three months' worth of ratings.

I5X Financial Forecast

I5X Earnings Forecast

Next quarter’s earnings estimate for I5X is >-CHF0.01 with a range of -CHF0.01 to >-CHF0.01. The previous quarter’s EPS was -CHF0.02. I5X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year I5X has Performed in-line its overall industry.
Next quarter’s earnings estimate for I5X is >-CHF0.01 with a range of -CHF0.01 to >-CHF0.01. The previous quarter’s EPS was -CHF0.02. I5X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year I5X has Performed in-line its overall industry.

I5X Sales Forecast

Next quarter’s sales forecast for I5X is CHF22.67M with a range of CHF22.04M to CHF23.04M. The previous quarter’s sales results were CHF18.84M. I5X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year I5X has Performed in-line its overall industry.
Next quarter’s sales forecast for I5X is CHF22.67M with a range of CHF22.04M to CHF23.04M. The previous quarter’s sales results were CHF18.84M. I5X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year I5X has Performed in-line its overall industry.

I5X Stock Forecast FAQ

What is CH:I5X’s average 12-month price target, according to analysts?
Based on analyst ratings, Precigen, Inc.’s 12-month average price target is 10.05.
    What is CH:I5X’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:I5X, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Precigen, Inc. a Buy, Sell or Hold?
        Precigen, Inc. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Precigen, Inc.’s share price target?
          The average share price target for Precigen, Inc. is 10.05. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF11.26 ,and the lowest forecast is CHF8.85. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Precigen, Inc.?
            Precigen, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
              How can I buy shares of Precigen, Inc.?
              To buy shares of CH:I5X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.